Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Blood - Tập 106 - Trang 3058-3061 - 2005
Yuval Shaked, Urban Emmenegger, Shan Man, Dave Cervi, Francesco Bertolini, Yaacov Ben-David, Robert S. Kerbel

Tóm tắt

Abstract Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy thought to have an antiangiogenic basis. However, the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term in this way with targeted therapies can be compromised by the empiricism associated with determining the optimum biologic dose (OBD). Using 4 distinct metronomic chemotherapy regimens in 4 different preclinical tumor models, including a hematologic malignancy, we established the OBD by determining the maximum efficacy associated with minimum or no toxicity. We then found each OBD to be strikingly correlated with the maximum reduction in viable peripheral blood circulating vascular endothelial growth factor receptor 2–positive (VEGFR-2+) endothelial precursors (CEPs). These results suggest that CEPs may serve as a pharmacodynamic biomarker to determine the OBD of metronomic chemotherapy regimens.

Tài liệu tham khảo

Hurwitz H, Fehrenbacher L, Novotny W, et al. Addition of bevacizumab (rhuMab VEGF) to bolus IFL in the first line treatment of patients with metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med.2004;350: 2335-2342. Kerbel RS, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer.2002;2: 727-739. Kerbel RS, Kamen BA. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer.2004;4: 423-436. Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res.2000;60: 1878-1886. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest.2000;105: 1045-1047. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res.2003;63: 4342-4346. Man S, Bocci G, Francia G, et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res.2002;62: 2731-2735. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest.2000;105: R15-R24. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemoswitch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol.2005;23: 939-952. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combinded with specific antitumor immunotherapy in a marine melanoma model. Cancer Res.2003;63: 8408-8413. Colleoni M, Rocca A, Sandri MT, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol.2002;13: 73-80. Glode LM, Crighton F, Barqawi A, Kerbel RS, Berman C, Crawford D. Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer.2003;98: 1643-1648. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med.2004;350: 1713-1721. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell.2005;7: 101-111. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med.2004;10: 145-147. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A.1991;88: 6028-6032. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft. Clin Cancer Res.2002;8: 221-232. Lee CR, Cervi D, Truong AH, Li YJ, Sarkar A, Ben David Y. Friend virus-induced erythroleukemias: a unique and well-defined mouse model for the development of leukemia. Anticancer Res.2003;23: 2159-2166. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res.2004;64: 3994-4000. Shaked Y, Cervi D, Neuman M, Pak B, Kerbel RS, Ben-David Y. Splenic microenvironment is a source of angiogenesis/inflammatory mediators accelerating the extramedullary expansion of murine erythroleukemic cells. Blood.2005;105: 4500-4507. Bocci G, Nicolaou KC, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res.2002;62: 6938-6943. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol.2001;12: 987-990. Buckstein R. Palliation of relapsed aggressive histology NHL with high-dose celecoxib and “metronomic” low-dose cyclophosphamide [abstract]. Proc Am Soc Clin Oncol.2004;23. Abstract 3016.
Thông tin
Thông tin xuất bản

Blood

Tập 106

3058-3061

Thông tin tác giả